Use of DPP-IV inhibitor to reduce hypoglycemic events

US8143217B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Boerk Balkan · Madison, US
• David Holmes · Binningen, CH
• Thomas E. Hughes · Boston, US
• Edwin Bernard Villhauer · Morristown, US

Key dates

• Filing date: Sep 18, 2006
• Grant date: Mar 27, 2012
• Expiry date: Jul 22, 2028

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a method to reduce the hypoglycemic events, especially sever hypoglycemic events resulting from insulin treatment, wherein the patient is treated with a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof.